Pasithea Therapeutics CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Pasithea Therapeutics reports a net loss of $2.9 million for Q1 2026 as it continues clinical development of its lead candidate, PAS-004.
NASDAQ
Pasithea Therapeutics reports continued clinical trial advancements for PAS-004 but faces significant operating losses and a going concern warning, necessitating further capital raises.
NASDAQ
Pasithea Therapeutics reported a reduced net loss for Q2 2025, driven by clinical trial advancements for PAS-004 and successful capital raises, but faces ongoing liquidity concerns and a Nasdaq minimum bid price deficiency.
NASDAQ
Pasithea Therapeutics reports a net loss of $3.56 million for Q1 2025 and provides an update on its clinical development programs and recent financing activities.
NASDAQ
10-Q: Pasithea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Clinical Update
Pasithea Therapeutics reported a net loss of $2.99 million for the third quarter of 2024, while also providing updates on their clinical trial for PAS-004 and a recent capital raise.
NASDAQ
Pasithea Therapeutics reported its Q2 2024 financial results, highlighting a net loss but also progress in its PAS-004 clinical trial.
NASDAQ
Pasithea Therapeutics reported a net loss of $3.86 million for the first quarter of 2024, while advancing its lead drug candidate, PAS-004, into Phase 1 clinical trials.